Journal of Mass Spectrometry and Advances in the Clinical Lab最新文献

{"title":"Corrigendum to “A liquid chromatography-high-resolution mass spectrometry method for separation and identification of hemoglobin variant subunits with mass shifts less than 1 Da” [J. Mass Spectromet. Adv. Clin. Lab 35 (2025) 1–7]","authors":"Ainslie Chen , Ryan M. Aquino , Hector A. Vidal , Carolyn V. Wong , Ruben Y. Luo","doi":"10.1016/j.jmsacl.2025.04.009","DOIUrl":"10.1016/j.jmsacl.2025.04.009","url":null,"abstract":"","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"37 ","pages":"Pages 14-15"},"PeriodicalIF":3.1,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced identification of Morganella spp. using MALDI-TOF mass spectrometry","authors":"Mathilde Duque ,&nbsp;Cécile Emeraud ,&nbsp;Rémy A. Bonnin ,&nbsp;Quentin Giai-Gianetto ,&nbsp;Laurent Dortet ,&nbsp;Alexandre Godmer","doi":"10.1016/j.jmsacl.2025.04.011","DOIUrl":"10.1016/j.jmsacl.2025.04.011","url":null,"abstract":"<div><h3>Introduction</h3><div>The genus <em>Morganella,</em> including clinically isolated species <em>M. sibonii</em> and <em>M. morganii</em>, has a still underexplored role in clinical microbiology. Despite the clinical relevance of <em>Morganella</em> spp., current MALDI-TOF commercial systems fail to differentiate these species. Whole genome sequencing (WGS) remains the most effective method to distinguish species. However, this method is not adapted for routine lab workflow. Enhancing MALDI-TOF’s accuracy could make it a rapid and effective approach for distinguishing <em>Morganella</em> species in routine laboratory diagnostics.</div></div><div><h3>Objectives</h3><div>This study aims to improve the performance of MALDI-TOF for identifying <em>Morganella</em> spp. using WGS as the gold-standard reference method.</div></div><div><h3>Methods</h3><div>We applied Machine Learning (ML) algorithms to a collection of 235 clinicial <em>Morganella</em> <!-->spp. strains to develop an optimized identification model. Whole genome sequencing was used to characterize these strains and perform phylogenetic analysis, categorizing 209 strains as <em>M. morganii</em> and 26 as <em>M. sibonii</em>.</div></div><div><h3>Results</h3><div>The ML-based classifiers showed improved identification accuracy (44 of the 160 designed with accuracy at<!--> <!-->1). Also, MS analysis identified 11 peaks able to discriminate between <em>M. morganii</em> and <em>M. sibonii</em>.</div></div><div><h3>Conclusion</h3><div>Through development of a publicly-available online ML-based classifier, this study has improved the capacity of MALDI-TOF for distinguishing <em>Morganella</em> spp<em>.</em>, providing a reliable, user-friendly solution suited to routine clinical diagnostics and supporting a better understanding of the roles of <em>M. morganii</em> and <em>M. sibonii</em> in human pathology.</div></div>","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"37 ","pages":"Pages 9-13"},"PeriodicalIF":3.1,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143912376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum peptides as candidate biomarkers for relapsing polychondritis","authors":"Toshiyuki Sato ,&nbsp;Masaaki Sato ,&nbsp;Kouhei Nagai ,&nbsp;Masahiko Fukasawa ,&nbsp;Yoshiaki Nagashima ,&nbsp;Teisuke Uchida ,&nbsp;Atsuhiro Tsutiya ,&nbsp;Kazuki Omoteyama ,&nbsp;Mitsumi Arito ,&nbsp;Yukiko Takakuwa ,&nbsp;Seido Ooka ,&nbsp;Naoya Suematsu ,&nbsp;Kimito Kawahata ,&nbsp;Yoshihisa Yamano ,&nbsp;Tomohiro Kato ,&nbsp;Manae S. Kurokawa","doi":"10.1016/j.jmsacl.2025.04.001","DOIUrl":"10.1016/j.jmsacl.2025.04.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Relapsing polychondritis (RP) is an intractable disease characterized by recurrent inflammation of cartilaginous tissue throughout the body. It is difficult to accurately diagnose RP, and no useful biomarkers have yet been identified.</div></div><div><h3>Objectives</h3><div>We analyzed serum peptide profiles to identify novel candidate biomarkers for RP.</div></div><div><h3>Methods</h3><div>Thirty-seven patients with RP, 42 patients with rheumatoid arthritis (RA), and 35 healthy control (HC) subjects were divided into training and testing sets. Seven patients demonstrating granulomatosis with polyangiitis (GPA) were used for validation. The ion intensity of serum peptides was comprehensively measured by matrix-assisted laser desorption/ionization time-of-flight/time-of-flight mass spectrometry and applied to a supervised multivariate analysis. Peptides of interest were analyzed by liquid chromatography-tandem mass spectrometry.</div></div><div><h3>Results</h3><div>In the training set, models developed based on 11 (RP/HC-11P model), 9 (RP/RA-9P model), and 14 (RP/nonRP-14P model) peptides, out of 160 peptides detected were able to completely discriminate the RP group from the HC, RA, and nonRP (HC + RA) groups. Almost all of the 15 identified discriminatory peptides comprising these models were fragments of proteins associated with coagulation. Four models, each consisting of 4 out of 10 identified peptides of the RP/nonRP-14P model (models RP/nonRP-4P-2, -10, -11, and -38), provided ≥ 70.0 % sensitivity and specificity when applied to the validation set (the testing set and the GPA group) (AUROC, 0.779–0.815). Notably, the RP/nonRP-4P-2 model provided 83.3 % sensitivity and 71.7 % specificity in the validation set (AUROC, 0.802).</div></div><div><h3>Conclusions</h3><div>Serum peptides are useful as candidate biomarkers for discriminating RP and may be involved in the pathophysiology of RP.</div></div>","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"37 ","pages":"Pages 28-38"},"PeriodicalIF":3.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144068933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-based estimation of biological variation in plasma-free amino acid concentrations among healthy adults","authors":"Müjgan Ercan ,&nbsp;Emiş Deniz Akbulut ,&nbsp;Ayşen Caniklioğlu ,&nbsp;Esra Fırat Oğuz ,&nbsp;Yakup Dülgeroğlu ,&nbsp;Esin Avcı ,&nbsp;Şerif Ercan","doi":"10.1016/j.jmsacl.2025.04.010","DOIUrl":"10.1016/j.jmsacl.2025.04.010","url":null,"abstract":"<div><h3>Introduction</h3><div>Free amino acid (FAA) analysis plays a crucial role in diagnosing and monitoring inborn errors of metabolism, assessing nutritional status, and identifying metabolic imbalances associated with various diseases. This study aimed to provide updated biological variation (BV) data to support the reliable clinical application of FAA concentrations in plasma samples, utilizing LC-MS/MS.</div></div><div><h3>Materials and methods</h3><div>Venous blood was collected from 22 healthy Turkish adults (9 men and 13 women) over approximately nine weeks. Plasma FAAs were measured in duplicate. BV estimates with 95 % confidence intervals were determined using nested ANOVA for the entire study group and sex-stratified subgroups, following analysis of outliers, normality, steady-state conditions, and variance homogeneity.</div></div><div><h3>Results</h3><div>Within-subject variation (CV_I) and between-subject variation (CV_G) estimates ranged from 9.5 % to 32.5 % and 8.6 % to 50.0 %, respectively. The estimated CV_I values for essential amino acids were significantly lower than those for non-essential amino acids (<em>P</em> = <em>0.03</em>). For most plasma FAAs, no significant differences in CV_I (except for alanine, arginine, glutamic acid, and threonine) or CV_G were observed between sexes. However, differences in the indices of individuality were noted between men and women for some plasma FAAs.</div></div><div><h3>Conclusions</h3><div>This Biological Variation Data Critical Appraisal Checklist-compliant study provides the first updated BV data for plasma FAAs. The significant variation observed in CV_I estimates is hypothesized to result from differences in the metabolic regulation of essential versus non-essential amino acids. The sex-stratified indices obtained in this study will aid in the appropriate application of population-based reference intervals for plasma FAA assessment.</div></div>","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"37 ","pages":"Pages 1-8"},"PeriodicalIF":3.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143899511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Definitive urine drug testing in emergency medicine: Recreational and psychiatric drug findings","authors":"Thomas G. Rosano ,&nbsp;S.M.Touhidul Islam ,&nbsp;John M. Rumberger ,&nbsp;Robert M. Konetchy Jr. ,&nbsp;Michelle Wood ,&nbsp;Joseph A. Sorce ,&nbsp;Karl A. Robstad ,&nbsp;Heather Long","doi":"10.1016/j.jmsacl.2025.04.008","DOIUrl":"10.1016/j.jmsacl.2025.04.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Clinical management of drug-related emergency department (ED) visits relies on available history, toxidrome findings and drug screening. In this study, definitive drug testing is used to assess ED drug prevalence and immunoassay drug screening performance.</div></div><div><h3>Methods</h3><div>Definitive testing for 116 drugs and metabolites was performed on urine from 400 ED patients, with comparison to immunoassay drug screening.</div></div><div><h3>Results</h3><div>Definitive testing resulted in 1,350 drug findings with prevalent use of nicotine (63%), cocaine (34%), ∆9 tetrahydrocannabinol (34%), fentanyl (17%), morphine or heroin (11%) and methamphetamine (6%). Forty percent of patients were also positive for antidepressants and 24% positive for antipsychotics. Significant patterns of co-drug use were found for cocaine, fentanyl, morphine and nicotine. Multi-serotonergic drug use was frequent, suggesting a risk for serotonin syndrome. Immunoassay performance showed high false negative rates for benzodiazepines (40%), amphetamines (38%), barbiturates (33%), opiates (25%), methadone (20%) and cocaine (16%), along with inaccuracy in phencyclidine detection. Immunoassay missed 890 of the 1,350 drug findings by definitive testing, due to either high cutoff thresholds or limited testing scope.</div></div><div><h3>Discussion</h3><div>A high prevalence of drugs use by ED patients is evidenced with frequent co-use of illicit and therapeutic drugs and with potential for unrecognized multi-serotonergic drug interactions. This study also shows the limitations of immunoassay drug testing in both scope and sensitivity, with a high rate of undetected drug use.</div></div><div><h3>Conclusion</h3><div>The study provides evidence-based support for recommended implementation of definitive drug testing in emergency medicine as a guide to clinical management in drug-related ED visits.</div></div>","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"37 ","pages":"Pages 16-27"},"PeriodicalIF":3.1,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of potential biomarkers for psoriasis in skin with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and ambient ionization mass spectrometry","authors":"Yi-Wen Hsu ,&nbsp;Hung Su ,&nbsp;Deng-Chyang Wu ,&nbsp;Chi-Wei Lee ,&nbsp;Sung-Jen Hung ,&nbsp;Jentaie Shiea","doi":"10.1016/j.jmsacl.2025.04.004","DOIUrl":"10.1016/j.jmsacl.2025.04.004","url":null,"abstract":"<div><h3>Background</h3><div>Psoriasis is a chronic inflammatory disease with an unclear etiology that affects skin, nails, and joints and often accompanies comorbidities. Recent studies indicate that alterations in metabolites within psoriatic lesions might be linked to inflammation. Studying bioactive lipid mediators or metabolites in skin inflammation and immunity might provide new potential biomarkers and therapeutic prediction factors.</div></div><div><h3>Methods</h3><div>Lipids and peptides in the scale extracts from psoriasis patients and healthy controls were characterized by thermal desorption-electrospray ionizationmass spectrometry and matrix-assisted laser desorption/ionization time-of-flightmass spectrometry, respectively. Principal component analysis (PCA) was then applied to these data to identify potential differences between psoriasis patients and healthy controls.</div></div><div><h3>Results</h3><div>Psoriatic plaques show reduced wax esters and triglycerides and a predominant increase in human neutrophil defensins (HNPs), compared to non-lesional sites of psoriatic patients and healthy control. Additionally, when medical treatments were administered to psoriasis patients, levels of HNPs were significantly reduced, suggesting that they may serve as potential biomarkers to evaluate therapeutic efficacy for psoriasis.</div></div><div><h3>Conclusion</h3><div>Two mass spectrometric techniques were used to rapidly and non-invasively identify and monitor potential biomarkers between psoriasis patients and healthy controls. However, PCA results only showed slight differences, and we intend to broaden the sample base in the future to increase the statistical power of the investigation.</div></div>","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"36 ","pages":"Pages 52-62"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of glucagon and oxyntomodulin by protein precipitation-immunoaffinity enrichment-LC-MS/MS","authors":"Jessica O. Becker ,&nbsp;Sara K. Shijo ,&nbsp;Huu-Hien Huynh ,&nbsp;Katrina L. Forrest ,&nbsp;Michael J. MacCoss ,&nbsp;Michelle A. Emrick ,&nbsp;Elisha Goonatilleke ,&nbsp;Andrew N. Hoofnagle","doi":"10.1016/j.jmsacl.2025.04.002","DOIUrl":"10.1016/j.jmsacl.2025.04.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Glucagon and oxyntomodulin are peptide hormones differentially released from proglucagon that function in regulating blood glucose. Their overlapping amino acid sequences make the development of specific immunoassays difficult, but the specificity of liquid chromatography-tandem mass spectrometry can be used to distinguish the peptides. We aimed to develop a sensitive and specific mass spectrometric assay that uses non-proprietary reagents and normal-flow liquid chromatography in the simultaneous quantification of both analytes.</div></div><div><h3>Methods</h3><div>Bulk plasma proteins were precipitated in ethanol/ammonium hydroxide. Analytes were enriched using monoclonal antibodies generated in-house and analyzed using liquid chromatography-tandem mass spectrometry. A glucagon calibration material was sourced commercially and characterized for purity and concentration by high-performance liquid chromatography-ultraviolet detection and amino acid analysis. Single-point calibration was used to minimize between-day variability.</div></div><div><h3>Results</h3><div>The novel antibodies performed acceptably (peptide recovery 45–59 %). The assay was precise (&lt;13 %CV) and linear over the range of 1.3–14.7 pM and 1.1–13.7 pM for glucagon and oxyntomodulin, respectively. The glucagon calibration material concentration was determined to be 1.596 mg/g. Tube-type studies supported the use of protease inhibitor tubes at the time of blood draw. Patients with type 1 diabetes had lower concentrations of glucagon when maintained on an insulin pump, but not with injectable insulin.</div></div><div><h3>Conclusion</h3><div>We have validated a method with a highly detailed standard operating procedure. We have characterized calibration materials to help maintain accuracy and achieve between-day and between-laboratory harmonization. The assay will be beneficial in better understanding α-cell health and glycemic control in diabetes and other diseases.</div></div>","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"36 ","pages":"Pages 37-45"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of an LC-MS/MS method for urinary homovanillic and vanillylmandelic ACIDS and application to the diagnosis of neuroblastoma","authors":"Lucilla Rossi ,&nbsp;Yvette A.H. Matser ,&nbsp;Sebastiano Barco ,&nbsp;Alessia Cafaro ,&nbsp;Federica Pigliasco ,&nbsp;Margherita Biondi ,&nbsp;Fabrizio Mancin ,&nbsp;Maria van der Ham ,&nbsp;Monique G.M. de Sain-van der Velden ,&nbsp;Shifra Ash ,&nbsp;Maja Beck Popovic ,&nbsp;André B.P. van Kuilenburg ,&nbsp;Massimo Conte ,&nbsp;Alberto Garaventa ,&nbsp;Godelieve A.M. Tytgat ,&nbsp;Giuliana Cangemi","doi":"10.1016/j.jmsacl.2025.04.007","DOIUrl":"10.1016/j.jmsacl.2025.04.007","url":null,"abstract":"<div><h3>Background</h3><div>Urinary catecholamine metabolites are well-established biomarkers for neuroblastoma (NB). Homovanillic acid (HVA) and vanillylmandelic acid (VMA) are the most frequently measured metabolites within SIOPEN – Catecholamine Working Group laboratories. Here, we evaluated the performance of a new LC-MS/MS in vitro diagnostic (IVD) kit for HVA and VMA to facilitate inter-laboratory harmonization.</div></div><div><h3>Methods</h3><div>HVA and VMA and their deuterated internal standards were analyzed with a commercial method, on a ThermoFisher Quantiva LC-MS/MS. Validation was performed first using internal quality control and external quality assessment (IQC and EQA) samples. Next by clinical validation on 120 samples, previously tested by HPLC-ECD. Finally, 36 samples were exchanged between SIOPEN reference laboratories and analyzed by three methods.</div></div><div><h3>Results</h3><div>Using QCs and EQA the method was validated in a wide calibration range (4.61–830 µmol/L for HVA and 4.44–800 µmol/L for VMA). Intra-day CVs (<em>n</em> = 5) were 7 and 8 % for HVA and 5 and 6 % for VMA for QC low and QC high, respectively; Inter-day CV% were 7 and 3 % for HVA and 2 and 7 % for VMA at QC low and QC high, respectively. Its application to 120 clinical samples confirmed a high diagnostic accuracy. The inter-laboratory quality control assessment showed interchangeable results (<em>p =</em> 0,73 and <em>p =</em> 0.15 for HVA and VMA, respectively).</div></div><div><h3>Conclusion</h3><div>The LC-MS/MS IVD method could be considered a useful tool for clinical laboratories involved in the measurement of catecholamines, contributing to harmonization efforts.</div></div>","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"36 ","pages":"Pages 73-81"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to “Identification of metabolites of brexpiprazole in human urine for use in monitoring patient compliance” [Clin. Mass Spectrom. 6 (2017) 21–24]","authors":"Jeffrey R. Enders ,&nbsp;Sandeep Gunna Reddy ,&nbsp;Erin C. Strickland ,&nbsp;Gregory L. McIntire","doi":"10.1016/j.jmsacl.2025.03.001","DOIUrl":"10.1016/j.jmsacl.2025.03.001","url":null,"abstract":"","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"36 ","pages":"Page 82"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of total sBCMA in human plasma by peptide-level immunocapture LC-MS/MS","authors":"Johanna Paris ,&nbsp;Alexandra Tavernier ,&nbsp;Sylvie Bethegnies,&nbsp;Sandrine Descloux,&nbsp;Olivier Fedeli","doi":"10.1016/j.jmsacl.2025.04.006","DOIUrl":"10.1016/j.jmsacl.2025.04.006","url":null,"abstract":"<div><h3>Background</h3><div>B-cell maturation antigen (BCMA) is a membrane protein that is overexpressed in multiple myeloma cells and can be targeted with biotherapeutic agents. BCMA is naturally shed by γ-secretase, leading to the formation of soluble BCMA (sBCMA), which circulates in the blood. sBCMA can affect the efficacy of BCMA-targeted therapies and act as a drug sink. Additionally, sBCMA can interfere with pharmacokinetic measurements when BCMA is directly targeted. Therefore, quantification of this biomarker during clinical trials is essential to assess the effective dose and understand pharmacokinetic results. When quantifying sBCMA using ligand binding assays or hybrid assays, the biotherapeutic can interfere with the capture of sBCMA, leading to an underestimation of its levels.</div></div><div><h3>Methods</h3><div>Samples were denatured, reduced, and alkylated prior to trypsin digestion. sBCMA peptide enrichment was performed using anti-peptide polyclonal antibodies. Reversed-phase chromatographic separation was conducted on a biocompatible C18 column with an analysis time of sixteen minutes per sample. The SCIEX QTRAP 5500 mass spectrometer operated in multiple reaction monitoring mode. The calibration curve was prepared by spiking recombinant sBCMA into monkey plasma.</div></div><div><h3>Results</h3><div>The parallelism between the authentic and surrogate matrices, as well as between the endogenous and recombinant proteins, was validated. Comparisons were made between protein and peptide level hybrid assays, with the peptide level approach effectively removing the interference of the biotherapeutic. Additionally, the peptide level immunocapture LC-MS/MS demonstrated ligand tolerance.</div></div><div><h3>Conclusion</h3><div>The peptide level immunocapture LC-MS/MS analysis eliminated the interference of anti-BCMA biotherapeutics, allowing for the quantification of total sBCMA in clinical samples while achieving a LLOQ of 10 ng/mL.</div></div>","PeriodicalId":52406,"journal":{"name":"Journal of Mass Spectrometry and Advances in the Clinical Lab","volume":"36 ","pages":"Pages 46-51"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}